Search Results - "FORONI, L"

Laboratory recommendations for scoring deep molecular responses following treatment for chronic myeloid leukemia by Cross, N C P, White, H E, Colomer, D, Ehrencrona, H, Foroni, L, Gottardi, E, Lange, T, Lion, T, Machova Polakova, K, Dulucq, S, Martinelli, G, Oppliger Leibundgut, E, Pallisgaard, N, Barbany, G, Sacha, T, Talmaci, R, Izzo, B, Saglio, G, Pane, F, Müller, M C, Hochhaus, A

“…Treatment of chronic myeloid leukemia (CML) with tyrosine kinase inhibitors has advanced to a stage where many patients achieve very low or undetectable levels…”
Get full text

Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia by Hochhaus, A, O'Brien, S G, Guilhot, F, Druker, B J, Branford, S, Foroni, L, Goldman, J M, Müller, M C, Radich, J P, Rudoltz, M, Mone, M, Gathmann, I, Hughes, T P, Larson, R A

“…Imatinib mesylate is considered standard of care for first-line treatment of chronic phase chronic myeloid leukemia (CML-CP). In the phase III, randomized,…”
Get full text

A randomised phase II trial of hydroxychloroquine and imatinib versus imatinib alone for patients with chronic myeloid leukaemia in major cytogenetic response with residual disease by Horne, G. A., Stobo, J., Kelly, C., Mukhopadhyay, A., Latif, A. L., Dixon-Hughes, J., McMahon, L., Cony-Makhoul, P., Byrne, J., Smith, G., Koschmieder, S., BrÜmmendorf, T. H., Schafhausen, P., Gallipoli, P., Thomson, F., Cong, W., Clark, R. E., Milojkovic, D., Helgason, G. V., Foroni, L., Nicolini, F. E., Holyoake, T. L., Copland, M.

“…In chronic-phase chronic myeloid leukaemia (CP-CML), residual BCR-ABL1 + leukaemia stem cells are responsible for disease persistence despite TKI. Based on in…”
Get full text

Analysis of minimal residual disease by Ig TCR gene rearrangements: guidelines for interpretation of real-time quantitative PCR data by VAN DER VELDEN, V. H. J, CAZZANIGA, G, CAYUELA, J. M, TRKA, J, ECKERT, C, FORONI, L, ZUR STADT, U, BELDJORD, K, RAFF, T, VAN DER SCHOOT, C. E, VAN DONGEN, J. J. M, SCHRAUDER, A, HANCOCK, J, BADER, P, PANZER-GRUMAYER, E. R, FLOHR, T, SUTTON, R, CAVE, H, MADSEN, H. O

“…Most modern treatment protocols for acute lymphoblastic leukaemia (ALL) include the analysis of minimal residual disease (MRD). To ensure comparable MRD…”
Get full text

Major response to pembrolizumab in two patients with locally advanced cutaneous squamous cell carcinoma by Degache, E., Crochet, J., Simon, N., Tardieu, M., Trabelsi, S., Moncourier, M., Templier, I., Foroni, L., Lemoigne, A., Pinel, N., Gil, H., Bouillet, L., Leccia, M. T., Charles, J.

Get full text

A certified plasmid reference material for the standardisation of BCR–ABL1 mRNA quantification by real-time quantitative PCR by White, H, Deprez, L, Corbisier, P, Hall, V, Lin, F, Mazoua, S, Trapmann, S, Aggerholm, A, Andrikovics, H, Akiki, S, Barbany, G, Boeckx, N, Bench, A, Catherwood, M, Cayuela, J-M, Chudleigh, S, Clench, T, Colomer, D, Daraio, F, Dulucq, S, Farrugia, J, Fletcher, L, Foroni, L, Ganderton, R, Gerrard, G, Gineikienė, E, Hayette, S, El Housni, H, Izzo, B, Jansson, M, Johnels, P, Jurcek, T, Kairisto, V, Kizilors, A, Kim, D-W, Lange, T, Lion, T, Polakova, K M, Martinelli, G, McCarron, S, Merle, P A, Milner, B, Mitterbauer-Hohendanner, G, Nagar, M, Nickless, G, Nomdedéu, J, Nymoen, D A, Leibundgut, E O, Ozbek, U, Pajič, T, Pfeifer, H, Preudhomme, C, Raudsepp, K, Romeo, G, Sacha, T, Talmaci, R, Touloumenidou, T, Van der Velden, V H J, Waits, P, Wang, L, Wilkinson, E, Wilson, G, Wren, D, Zadro, R, Ziermann, J, Zoi, K, Müller, M C, Hochhaus, A, Schimmel, H, Cross, N C P, Emons, H

“…Serial quantification of BCR–ABL1 mRNA is an important therapeutic indicator in chronic myeloid leukaemia, but there is a substantial variation in results…”
Get full text

Nerve transfers for acute flaccid myelitis: a case series by Heise, C. O., de Oliveira, A. J., Bhering, T., Martins, R. S., Sterman-Neto, H., Foroni, L., Siqueira, M. G.

“…Background Acute flaccid myelitis (AFM) syndrome consists of loss of lower motor neurons following a viral infection, with preserved sensory function. It…”
Get full text

Powerful strategy for polymerase chain reaction-based clonality assessment in T-cell malignancies Report of the BIOMED-2 Concerted Action BHM4 CT98-3936 by BRÜGGEMANN, M, WHITE, H, TIEMANN, M, HERBST, H, LANGERAK, A. W, SPAARGAREN, M, MOREAU, E, GROENEN, P. J. T. A, SAMBADE, C, FORONI, L, CARTER, G. I, HUMMEL, M, GAULARD, P, BASTARD, C, DAVI, F, DELFAU-LARUE, M.-H, KNEBA, M, VAN DONGEN, J. J. M, BELDJORD, K, MOLINA, Tj, GARCIA-SANZ, R, GAMEIRO, P, OESCHGER, S., JASANI, B, OTT, M, DELSOL, G, ORFAO, A

“…Polymerase chain reaction (PCR) assessment of clonal T-cell receptor (TCR) and immunoglobulin (Ig) gene rearrangements is an important diagnostic tool in…”
Get full text

Dual Glutathione-S-Transferase-θ1 and -μ1 Gene Deletions Determine Imatinib Failure in Chronic Myeloid Leukemia by Davies, A, Giannoudis, A, Zhang, J E, Austin, G, Wang, L, Holyoake, T L, Müller, M C, Foroni, L, Kottaridis, P D, Pirmohamed, M, Clark, R E

“…Approximately 40% of patients with chronic myeloid leukemia (CML) receiving imatinib fail treatment. There is an increased risk of CML in subjects with (i)…”
Get full text

Antigen receptor stereotypy across B-cell lymphoproliferations: the case of IGHV4-59/IGKV3-20 receptors with rheumatoid factor activity by Kostareli, E, Gounari, M, Janus, A, Murray, F, Brochet, X, Giudicelli, V, Pospisilova, S, Oscier, D, Foroni, L, di Celle, P F, Tichy, B, Pedersen, L B, Jurlander, J, Ponzoni, M, Kouvatsi, A, Anagnostopoulos, A, Thompson, K, Darzentas, N, Lefranc, M-P, Belessi, C, Rosenquist, R, Davi, F, Ghia, P, Stamatopoulos, K

Get full text

P713: REAL‐WORLD MANAGEMENT OF PATIENTS WITH CHRONIC MYELOID LEUKAEMIA (CML): FIRST ANALYSIS FROM THE UK NATIONAL REGISTRY FOR CML by Nesr, G., Szydlo, R., Braithwaite, B., Frackelton, S., Mathew, P., Hashmi, M., Fernando, F., Innes, A., Claudiani, S., Khan, A., Rao, A., Foroni, L., Milojkovic, D., Apperley, J. F., Clark, R. E.

Get full text

Mesenchymal stem cell interaction with a non‐woven hyaluronan‐based scaffold suitable for tissue repair by Pasquinelli, G., Orrico, C., Foroni, L., Bonafè, F., Carboni, M., Guarnieri, C., Raimondo, S., Penna, C., Geuna, S., Pagliaro, P., Freyrie, A., Stella, A., Caldarera, C. M., Muscari, C.

“…Summary The fabrication of biodegradable 3‐D scaffolds enriched with multipotent stem cells seems to be a promising strategy for the repair of irreversibly…”
Get full text

KIR2DS1 genotype predicts for complete cytogenetic response and survival in newly diagnosed chronic myeloid leukemia patients treated with imatinib by Marin, D, Gabriel, I H, Ahmad, S, Foroni, L, Lavallade, H de, Clark, R, O'Brien, S, Sergeant, R, Hedgley, C, Milojkovic, D, Khorashad, J S, Bua, M, Alsuliman, A, Khoder, A, Stringaris, K, Cooper, N, Davis, J, Goldman, J M, Apperley, J F, Rezvani, K

“…Natural killer (NK) cells are expanded in chronic myeloid leukemia (CML) patients on tyrosine kinase inhibitors (TKI) and exert cytotoxicity. The inherited…”
Get full text

Impact of systemic antifungal therapy on the detection of Candida species in blood cultures in clinical cases of candidemia by Bailly, S., Garnaud, C., Cornet, M., Pavese, P., Hamidfar-Roy, R., Foroni, L., Boisset, S., Timsit, J.-F., Maubon, D.

“…The diagnosis and follow-up of candidemia still rely on blood cultures (BCs). In vitro studies show that antifungals can significantly modify the result of…”
Get full text

P706: ASCIMINIB USE IN CML: THE UK EXPERIENCE by Innes, A., Orovboni, V., Claudiani, S., Fernando, F., Khan, A., Byrne, J., Gallipoli, P., Copland, M., Horne, G., Arnold, C., Collins, A., Cunningham, N., Danga, A., Frewin, R., Garland, P., Hannah, G., Hassan, S., Makkuni, S., Rothwell, K., Foroni, L., Hayden, C., Apperley, J., Milojkovic, D.

Get full text

hOCT1 transcript levels and single nucleotide polymorphisms as predictive factors for response to imatinib in chronic myeloid leukemia by Bazeos, A, Marin, D, Reid, A G, Gerrard, G, Milojkovic, D, May, P C, de Lavallade, H, Garland, P, Rezvani, K, Apperley, J F, Goldman, J M, Foroni, L, Khorashad, J S

Get full text

High incidence of Notch-1 mutations in adult patients with T-cell acute lymphoblastic leukemia by Mansour, M R, Linch, D C, Foroni, L, Goldstone, A H, Gale, R E

Get full text

Null Mutation of the Lmo4 Gene or a Combined Null Mutation of the Lmo1/Lmo3 Genes Causes Perinatal Lethality, and Lmo4 Controls Neural Tube Development in Mice by Tse, E., Smith, A. J. H., Hunt, S., Lavenir, I., Forster, A., Warren, A. J., Grutz, G., Foroni, L., Carlton, M. B. L., Colledge, W. H., Boehm, T., Rabbitts, T. H.

“…Article Usage Stats Services MCB Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley…”
Get full text

Escalating-dose HLA-mismatched DLI is safe for the treatment of leukaemia relapse following alemtuzumab-based myeloablative allo-SCT by Innes, A J, Beattie, R, Sergeant, R, Damaj, G, Foroni, L, Marin, D, Kanfer, E, Mielke, S, Milojkovic, D, MacDonald, D, Pavlu, J, Rahemtulla, A, Roberts, I, Slade, D, Bray, E, Goldman, J, Apperley, J, Szydlo, R, Dazzi, F, Rezvani, K

“…Although the feasibility of using HLA-mismatched unrelated donors as an alternate graft source for haematopoietic SCT (HSCT) has been shown, little is known…”
Get full text

Dysfunctional Vasa Vasorum in Diabetic Peripheral Artery Obstructive Disease with Critical Lower Limb Ischaemia by Orrico, C, Pasquinelli, G, Foroni, L, Muscarà, D, Tazzari, P.L, Ricci, F, Buzzi, M, Baldi, E, Muccini, N, Gargiulo, M, Stella, A

“…Abstract Objectives and design To establish whether in diabetic patients with peripheral artery obstructive disease (PAOD) vasa vasorum (vv) neoangiogenesis is…”
Get full text